Clinical trial
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
NCT00093951 · Saegis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00093951 |
|---|---|
| Title | SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Saegis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | SGS742 |
| Enrollment | 280 |
| Start date | Apr 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Oct 8, 2004 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: